Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenic

Toxicology in Vitro

Volumn 28, Issue 7, 2014, Pages 1196-1205

  Gentry, P R ^a   Yager, J W ^a,c   Clewell, R A ^b   Clewell, H J ^b  

^a ENVIRON INTERNATIONAL CORPORATION   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Arsenic; Bladder; Genomics; In vitro; Mode of action; Risk assessment

Indexed keywords

ARSENIC; DRINKING WATER; INORGANIC COMPOUND; CARCINOGEN; WATER POLLUTANT;

ARTICLE; BLADDER CANCER; CONCENTRATION (PARAMETERS); DATA ANALYSIS; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; MOLECULAR WEIGHT; NONHUMAN; PREDICTION; PRIMARY CELL; SIGNAL TRANSDUCTION; WATER ANALYSIS; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; PHARMACOKINETICS; RISK ASSESSMENT; STANDARDS; TOXICITY; URINARY BLADDER NEOPLASMS; WATER POLLUTANT;

ANIMALS; ARSENIC; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; MICE; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS; WATER POLLUTANTS, CHEMICAL;

EID: 84903907468     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.05.011     Document Type: Article

References (93)

1. Agusa, T., Trang, P.T.K., Lan, V.M., Anh, D.H., Tanabe, S., Viet, P.H., Berg, M., 2013. Human exposure to arsenic from drinking water in Vietnam. Sci. Total. Environ., in press. doi:10.1016/j.scitotenv.2013.10.039.
2. ATSDR, 2007. Toxicological Profile for Arsenic. Atlanta, GA, United States Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. <>. http://www.%20atsdr.cdc.gov/toxprofiles/tp2.html.
3. Baastrup R., Sorensen M., Balstrom T., Frederiksen K., Larsen C.L., Tjonneland A., Overvad K., Nielsen O. Arsenic in drinking-water and risk for cancer in Denmark. Environ. Health Perspect. 2008, 116(2):231-237.
4. Bates M.N., Smith A.H., Cantor K.P. Case-control study of bladder cancer and arsenic in drinking water. Am. J. Epidemiol. 1995, 141(6):523-530.
5. Benton M.A., Rager J.E., Smeester L., Fry R.C. Comparative genomic analyses identify common molecular pathways modulated upon exposure to low doses of arsenic and cadmium. BMC Genom. 2011, 12(173):1-10.
6. Bukowski J.A., Lewis R.J. Practical implications of nonlinear effects in risk-assessment harmonization. Nonlinear. Biol. Toxicol. Med. 2004, 2(1):3-10.
7. Burgess J.L., Meza M.M., Josyula A.B., Poplin G.S., Kopplin M.U., McClellen H.E., Sturup S., Lantz R.C. Environmental arsenic exposure and urinary 8-OHdG in Arizona and Sonora. Clin. Toxicol. 2007, 45:490-498. As cited in Normandin et al. 2013.
8. Chen C.-J., Chuang Y.-C., You S.-L., Lin T.-M., Wu H.Y. A retrospective study on malignant neoplasma of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br. J. Cancer 1986, 53:399-405.
9. Chen C.-J., Kuo T.-L., Wu M.-M. Arsenic and cancers. The Lancet 1988, 20(February):414-415.
10. Chen H., Li S.F., Liu J., Diwan B.A., Barrett J.C., Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004, 25(9):1779-1786.
11. Chen C.L., Chiou H.Y., Hsu L.I., Hsueh Y.M., Wu M.M., Wang Y.H., Chen C.J. Arsenic in drinking water and risk of urinary tract cancer: a follow up from northeastern Taiwan. Cancer Epidem. Biomar. 2010, 19(1):101-110.
12. Chen S., Wang Y., Hsu J., Chang H., Wang C., Shen P., Chiang C., Chuang J., Tsai H., Gu P., Chang F., Liu H., Chow N. Nucloephosmin in the pathogenesis of arsenic-related bladder carcinogenesis revealed by quantitative proteomics. Toxicol. Appl. Pharmacol. 2010, 242:126-135.
13. Chen B., Arnold L.L., Cohen S.M., Thomas D.J., Le X.C. Mouse arsenic (+3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water. Toxicol. Sci. 2011, 124(2):320-326.
14. Chiou H.-Y., Hsueh Y.-M., Liaw K.-F., Horng S.-F., Chiang M.-H., Pu Y.-S., Lin J.S.-N., Huang C.-H., Chen C.-J. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995, 55:1296-1300.
15. Chiou H., Chiou S., Hsu Y., Chou Y., Tseng C., Wei M., Chen C. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 in an arseniasis-endemic area in northeastern Taiwan. Am. J. Epidemiol. 2001, 153(5):411-418.
16. Clewell H.J., Crump K.S. Quantitative estimates of risk for noncancer endpoints. Risk Anal. 2005, 25(2):285-289.
17. Clewell H.J., Thomas R.S., Kenyon E.M., Hughes M.F., Adair B.M., Gentry P.R., Yager J.W. Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeks. Toxicol. Sci. 2011, 123(2):421-432. Epub.
18. Cohen S.M., Arnold L.L., Eldan M., Lewis A.S., Beck B.D. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol. 2006, 36(2):99-133.
19. Cohen S.M., Ohnishi T., Arnold L.L., Le X.C. Arsenic-induced bladder cancer in an animal model. Toxicol. Appl. Pharmacol. 2007, 222:258-263.
20. Crump K.S. The effect of random error in exposure measurement upon the shape of the exposure response. Dose-Response 2005, 3:456-464.
21. Cuzick, J., Sasieni, P., Evans, S., 1992. Ingested arsenic, keratosis, and bladder cancer. 136(4), 417-421.
22. Del Razo, L.M., Hernandez, J.L., Garcia-Vargas, G.G., Ostrosky-Wegman, P., Cortinas, C., Cebrian, M.E., 1994. Urinary excretion of arsenic in a human population chronically exposed to arsenic via drinking water. A pilot study. In: Chappell, W.R., Abernathy, C.O., Cothern, C.R. (Eds.), Arsenic Exposure and Health. Science Reviews, vol. 40, pp. 91-100.
23. Del Razo L.M., Garcia-Vargas G.G., Vargas H., Albores A., Gonsebatt M.E., Montero R., Ostrosky-Wegman P., Kelsh M., Cebrian M.E. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. Arch. Toxicol. 1997, 71(4):211-217.
24. Del Razo L.M., Garcia-Vargas G.G., Valenzuela O.L., Castellanos E.H., Sanchez-Pena L.C., Currier J.M., Drobna Z., Loomis D., Styblo M. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapan and Lagunera regions in Mexico. Environ. Health 2011, 10(73):1-11.
25. EFSA, 2009. Scientific opinion on arsenic in food. EFSA Panel on Contaminants in Food Chain (CONTAM). European Food Safety Authority, Parma, Italy. EFSA J. 7(10), 1351.
26. El-Masri H.A., Kenyon E.M. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. J. Pharmacokinet. Pharmacodynam. 2008, 35(1):31-68.
27. Enterline P.E., Henderson V.L., Marsh G.M. Exposure to arsenic and respiratory cancer. A reanalysis. Am. J. Epidemiol. 1987, 125(6):929-938.
28. EPA, 1993. Reference Dose (RfD): Description and Use in Health Risk Assessments. Integrated Risk Information System (IRIS). US Environmental Protection Agency. Background Document 1A. March 15, 1993.
29. EPA, 2005. Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001F.
30. Farmer J.G., Johnson L.R. Assessment of occupational exposure to inorganic arsenic based on urinary concentrations and speciation of arsenic. Br. J. Ind. Med. 1990, 47(5):342-348.
31. Ferreccio C., Gonzalez C., Miosavjlevic V., Marshall G., Sancha A.M., Smith A.H. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000, 11(6):673-679.
32. Fillol C., Dor F., Labat L., Boltz P., Le Bouard J., Mantey K., Mannschott C., Puskarczyk E., Viller F., Momas I., Seta N. Urinary arsenic concentrations and speciation in residents living in an area with naturally contaminated soils. Sci. Total Environ. 2010, 408(5):1190-1194.
33. Fujino Y., Guo X., Liu J., Matthew I.P., Shirane K., Wu K., Kasai H., Miyatake M., Tanabe K., Kusuda T., Yoshimura T. Chronic arsenic exposure and urinary 8-hydroxy-Z'-deoxyguanosine in an arsenic-affected area in Inner Mongolia, China. J. Expo. Anal. Environ. Epidemiol. 2005, 15:147-152. As cited in Normandin et al. 2013.
34. Gentry P.R., McDonald T.B., Sullivan D.E., Shipp A.M., Yager J.W., Clewell H.J. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ. Mol. Mutagen. 2010, 51:1-14.
35. Gentry P.R., Clewell H.J., Greene T.B., Franzen A.C., Yager J.W. The impact of recent advances in research on arsenic cancer risk assessment. Reg. Toxicol. Pharm. 2014, 69(1):91-104.
36. Gilmour M.I., Jaakkola M.S., London S.J., Nel A.E., Rogers C.A. How exposure to environmental tobacco smoke, outdoor air pollutants, and increased pollen burdens influences the incidence of asthma. Environ. Health Perspect. 2006, 114(4):627-633.
37. Guo H.R., Chiang H., Hu H., Lipsitz S.R., Monson R.R. Arsenic in drinking water and incidence of urinary cancers. Epidemiology 1997, 8(5):545-550.
38. Han Y., Weissfeld J.L., Davis D.L., Talbott E.O. Arsenic levels in ground water and cancer incidence in Idaho: an ecologic study. Int. Arch. Occup. Environ. Health 2009, 82:843-849.
39. Hays S.M., Aylward L.L., Gagne M., Nong A., Krishnan K. Biomonitoring equivalents for inorganic arsenic. Reg. Toxicol. Pharm. 2010, 58:1-9.
40. Hopenhayn-Rich C., Biggs M.L., Kalman D.A., Moore L.E., Smith A.H. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ. Health Perspect. 1996, 104(11):1200-1207.
41. International Agency for Research Council (IARC), 1987. Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1 to 42. IARC Monogr. Eval. Carcinog. Risks. Hum. Suppl. 7, 1-440. As cited in Normandin et al. 2013.
42. International Agency for Research Council (IARC), 2004. Some drinking-water disinfectants and contaminants, including arsenic. Summary of data reported and evaluation. IARC. Monog. Eval. Carcinog. Risks Hum. 84, 269-477. As cited in Normandin et al. 2013.
43. IPCS, 2005. Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/Concentration-response Assessment. Harmonization Project Document No. 2. International Programme on Chemical Safety (IPCS), World Health Organization, Geneva.
44. Jackson B.P., Taylor V.F., Karagas M.R., Punshon T., Cottingham K.L. Arsenic, organic foods and brown rice syrup. Environ. Health Perspect. 2012, 120(5):623-626.
45. Karagas M.R., Tosteson T.D., Morris J.S., Demidenko E., Mott L.A., Heany J., Schned A. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Cause Control 2004, 15:465-472.
46. Kile M.L., Hoffman E., Hsueh Y.M., Afroz S., Quamruzzaman Q., Rahman M., Mahiuddin G., Ryan L., Christiani D.C. Variability in biomarkers of arsenic exposure and metabolism in adults over time. Environ. Health Perspect. 2009, 117(3):455-460.
47. Kitchin K.T., Conolly R. Arsenic-induced carcinogenesis-oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. Chem. Res. Toxicol. 2010, 23(2):327-335.
48. Kitchin K.T., Wallace K. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha. Toxicol. Appl. Pharmacol. 2005, 206:66-72.
49. Kitchin K.T., Wallace K. Evidence against the nuclear in situ binding of arsenicals - oxidative stress theory of arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 2008, 232(2):252-257.
50. Klein C.B., Leszczynska J., Hickey C., Rossman T.G. Further evidence against a direct genotoxic mode of action for arsenic-induced cancer. Toxicol. Appl. Pharmacol. 2007, 222:289-297.
51. Lamm S.H., Engel A., Kruse M.B., Feinleib M., Byrd D.M., Lai S., Wilson R. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S. counties and 30 years of observation. JOEM 2004, 46(3):298-306.
52. Lewis D.R., Southwick J.W., Ouellet-Hellstrom R., Rench J., Calderon R.L. Drinking water arsenic in Utah: a cohort mortality study. Environ. Health Perspect. 1999, 107(5):359-365.
53. Li J.H., Rossman T.G. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. Mol. Toxicol. 1989, 2(1):1-9.
54. Mandal B.K., Ogra Y., Suzuki K.T. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 2001, 14(4):371-378.
55. Mann S., Droz P., Vahter M. A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. Toxicol. Appl. Pharmacol. 1996, 137:8-22.
56. Mann S., Droz P., Vahter M. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol. Appl. Pharmacol. 1996, 140:471-486.
57. Meliker J.R., Slotnick M.J., AvRuskin G.A., Schottenfeld D., Jacquez G.M., Wilson M.L., Goovaerts P., Franzblau A., Nriagu J.O. Lifetime exposure to arsenic in drinking water and bladder cancer: a population-based case-control study in Michigan, USA. Cancer Cause Control 2010, 21:745-757.
58. Mink P.J., Alexander D.D., Barraj L.M., Kelsh M.A., Tsuji J.S. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Reg. Toxicol. Pharm. 2008, 52:299-310.
59. Mostafa M.G., McDonald J.C., Cherry N.M. Lung cancer and exposure to arsenic in rural Bangladesh. Occup. Environ. Med. 2008, 65:765-768.
60. Nascimento M.G., Suzuki S., Wei M., Tiwari A., Arnold L.L., Lu X., Le X.C., Cohen S.M. Cytotoxicity of combinations of arsenicals on rat urinary bladder urothelial cells in vitro. Toxicology 2008, 249:69-74.
61. Normandin L., Ayotte P., Levallois P., Ibanez Y., Courteau M., Kennedy G., Chen L., Le X.C., Bouchard M. Biomarkers of arsenic exposure and effects in a Canadian rural population exposed through groundwater consumption. J. Expos. Sci. Environ. Epidemiol. 2013, 1-8.
62. National Research Council (NRC), 1999. Arsenic in Drinking Water. National Research Council. Subcommittee on Arsenic in Drinking Water, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission on Life Sciences, Washington, DC.
63. National Research Council (NRC), 2001. Arsenic in Drinking Water 2001 Update. National Research Council. Subcommittee to Update the 1999 Arsenic in Drinking Water Report. Committee on Toxicology, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies, National Research Council.
64. National Research Council (NRC) Toxicity Testing in the Twenty-First Century: A Vision and a Strategy 2007, National Academies Press, Washington, DC.
65. National Research Council (NRC), 2013. Critical Aspects of the EPA's IRIS Assessment of Inorganic Arsenic: Interim Report. Committee on Inorganic Arsenic, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies. The National Academies Press, Washington, DC.
66. Preston R.J. DNA reactivity as a mode of action and its relevance to cancer risk assessment. Toxicol. Pathol. 2013, 41(2):322-325.
67. Qin X.-J., Hudson L.G., Liu W., Ding W., Cooper K.L., Liu K.J. Dual actions involved in arsenite-induced oxidative DNA damage. Chem. Res. Toxicol. 2008, 21:1806-1813.
68. Rhomberg L.R. Toxicity testing in the 21st century: how will it affect risk assessment?. J. Toxicol. Environ. Health 2010, 13(2-4):361-375.
69. Rivera-Nunez A., Meliker J.R., Meeker J.D., Slotnick M.J., Nriagu J.O. Urinary arsenic species, toenail arsenic, and arsenic intake estimates in a Michigan population with low levels of arsenic in drinking water. J. Expo. Sci. Environ. Epidemiol. 2012, 22(2):182-190.
70. Smith T.J., Crecelius E.A., Reading J.C. Airborne arsenic exposure and excretion of methylated arsenic compounds. Environ. Health Perspect. 1977, 19:89-93.
71. Snow E.T., Sykora P., Durham T.R., Klein C.B. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol. Appl. Pharmacol. 2005, 207(2):557-564.
72. Steinmaus C., Yuan Y., Bates M.N., Smith A.H. Case-control study of bladder cancer and drinking water arsenic in the western United States. Am. J. Epidemiol. 2003, 158(12):1193-1201.
73. Straif K., Benbrahim-Tallaa L., Baan R., Grosse Y., Secretan B.E., Ghissassi F., Bourard V., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens - part C. Metals, arsenic, dust and fibres. Lancet Oncol. 2009, 10(5):453-454.
74. Sun G., Xu Y., Li X., Jin Y., Li B., Sun X. Urinary arsenic metabolites in children and adults exposed to arsenic in drinking water in Inner Mongolia, China. Environ. Health Perspect. 2007, 115(4):648-652.
75. Thomas R.S., Wesselkamper S.C., Wang N.C., Zhao Q.J., Petersen D.D., Lambert J.C., Cote I., Yang L., Healy E., Black M.B., Clewell H.J., Allen B.C., Andersen M.E. Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol. Sci. 2013, 134(1):180-194.
76. Torres-Escribanos S., Leal M., Velez D., Montero R. Total and inorganic arsenic concentrations in rice sold in Spain: effect of cooking and risk assessments. Environ. Sci. Technol. 2008, 42:3867-3872.
77. Tsuda T., Babazono A., Yamamoto E., Kurumatani N., Mino Y., Ogawa T., Kishi Y., Aoyama H. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am. J. Epidemiol. 1995, 141(3):198-209.
78. Tsuji J.S., Alexander D.D., Perez V. Low-level arsenic in drinking water and bladder cancer risks: meta-analysis update and risk assessment implications. Toxicol. Sci. 2013, 132(1):477.
79. Vahidnia A., Pablo R.F., van der Voet G.B., van der Straaten R.J.H.M., de Wolff F.A. Comparative toxicity of arsenite metabolites in wild type cho cells and in cells deficient in excision repair cross-complementing 1 and 2. Toxicol. in Vitro 2008, 22:1662-1665.
80. Valenzuela O.L., Borja-Aburto V.H., Garcia-Vargas G.G., Cruz-Gonzalez M.B., Garcia-Montalvo E.A., Calderon-Aranda E.S., Del Razo L.M. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic 2005, 113(3):250-254.
81. Wang T.-C., Jan K.-Y., Wang A.S., Gurr J.-R. Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells. Mutat. Res. 2007, 615:75-86.
82. Wei M., Arnold L.L., Cano M., Cohen S.M. Effect of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium. Toxicol. Sci. 2005, 83:237-245.
83. Welch K., Higgins I., Oh M., Burchfiel C. Arsenic exposure, smoking and respiratory cancer in copper smelter workers. Arch. Environ. Health 1982, 37(6):325-335.
84. West J.D., Marnett L.J. Alterations in gene expression induced by the lipid peroxidation product, 4-hydroxy-2-nonenal. Chem. Res. Toxicol. 2005, 18(11):1642-1653.
85. Xue J., Zartarian V., Wang S.-W., Liu S.V., Georgopoulos P. Probabilistic modeling of dietary arsenic exposure and dose and evaluation with 2003-2004 NHANES data. Environ. Health Perspect. 2010, 118:345-350.
86. Yager J.W., Wiencke J.K. Enhancement of chromosomal damage by arsenic: implications for mechanism. Environ. Health Perspect. Suppl. 1993, 101(3):79-82.
87. Yager J.W., Wiencke J.K. Inhibition of poly(ADP-ribose) polymerase by arsenite. Mutat. Res. 1994, 386:345-351.
88. Yager J.W., Gentry P.R., Thomas R.S., Pluta L., Efremenko A., Black M., Arnold L.L., McKim J.M., Wilga P., Gill G., Choe K.Y., Clewell H.J. Evaluation of gene expression changes in human primary uroepithelial cells following 24 hour exposures to inorganic arsenic and its methylated metabolites. Environ. Mol. Mutagen. 2013, 54(2):82-98.
89. Yager J.W., Efremenko A., Black M., Arnold L.L., Gentry P.R., Clewell H.J. Genomic changes in primary human uroepithelial cells following exposure to arsenite for up to 60 days. Environ. Mol. Mutagen. 2013, 54(S1):S38. (Abstract).
90. Yamauchi H., Takahashi K., Mashiko M., Yamamura Y. Biological monitoring of arsenic exposure of gallium arsenide- and inorganic arsenic-exposed workers by determination of inorganic arsenic and its metabolites in urine and hair. Am. Ind. Hyg. Assoc. J. 1989, 50(11):606-612.
91. Yamauchi H., Aminaka Y., Yoshida K., Sun G., Pi J., Waalkes M.P. Evaluation of DNA damage in patients with arsenic poisoning: urinary 8-hydroxydeoxyguanine. Toxicol. Appl. Pharmacol. 2004, 198:291-296. As cited in Normandin et al. 2013.
92. Yuan Y., Marshall G., Ferreccio C., Steinmaus C., Liaw J., Bates M., et al. Kidney cancer mortality: fifty-year latency patterns related to arsenic exposure. Epidemiology 2010, 21:103-108. As cited in. Nomandin et al. 2013.
93. Zhou X., Sun X., Cooper K.L., Wang F., Liu K.J., Hudson L.G. Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J. Biol. Chem. 2011, 286(26):22855-22863.